192 related articles for article (PubMed ID: 24942334)
81. RAS, BRAF, and TP53 gene mutations in Taiwanese colorectal cancer patients.
Chang YS; Chang SJ; Yeh KT; Lin TH; Chang JG
Onkologie; 2013; 36(12):719-24. PubMed ID: 24356563
[TBL] [Abstract][Full Text] [Related]
82. Cetuximab-mediated ADCC activity is correlated with the cell surface expression level of EGFR but not with the KRAS/BRAF mutational status in colorectal cancer.
Seo Y; Ishii Y; Ochiai H; Fukuda K; Akimoto S; Hayashida T; Okabayashi K; Tsuruta M; Hasegawa H; Kitagawa Y
Oncol Rep; 2014 May; 31(5):2115-22. PubMed ID: 24626880
[TBL] [Abstract][Full Text] [Related]
83. A combined oncogenic pathway signature of BRAF, KRAS and PI3KCA mutation improves colorectal cancer classification and cetuximab treatment prediction.
Tian S; Simon I; Moreno V; Roepman P; Tabernero J; Snel M; van't Veer L; Salazar R; Bernards R; Capella G
Gut; 2013 Apr; 62(4):540-9. PubMed ID: 22798500
[TBL] [Abstract][Full Text] [Related]
84. The Prognostic Utilities of DNA Mismatch Repair Status and KRAS and BRAF Mutation in Korean Colorectal Cancer Patients: The KASID Multicenter Study.
Kim TW; Hwang SW; Kim KO; Cha JM; Joo YE; Cho YS
Oncology; 2023; 101(1):49-58. PubMed ID: 36191562
[TBL] [Abstract][Full Text] [Related]
85. Changes in mutational status during third-line treatment for metastatic colorectal cancer--results of consecutive measurement of cell free DNA, KRAS and BRAF in the plasma.
Spindler KL; Pallisgaard N; Andersen RF; Jakobsen A
Int J Cancer; 2014 Nov; 135(9):2215-22. PubMed ID: 24659028
[TBL] [Abstract][Full Text] [Related]
86.
Habashy P; Lea V; Wilkinson K; Wang B; Wu XJ; Roberts TL; Ng W; Rutland T; Po JW; Becker T; Descallar J; Lee M; Mackenzie S; Gupta R; Cooper W; Lim S; Chua W; Lee CS
Int J Mol Sci; 2023 Dec; 24(24):. PubMed ID: 38139338
[No Abstract] [Full Text] [Related]
87. VEGFA gene locus (6p12) amplification identifies a small but highly aggressive subgroup of colorectal cancer [corrected] patients.
Vlajnic T; Andreozzi MC; Schneider S; Tornillo L; Karamitopoulou E; Lugli A; Ruiz C; Zlobec I; Terracciano L
Mod Pathol; 2011 Oct; 24(10):1404-12. PubMed ID: 21743435
[TBL] [Abstract][Full Text] [Related]
88. Prognostic value of BRAF/MIR-17 signature and B-Raf protein expression in patients with colorectal cancer: A pilot study.
Ibrahiem AT; Fawzy MS; Abu AlSel BT; Toraih EA
J Clin Lab Anal; 2021 Mar; 35(3):e23679. PubMed ID: 33296098
[TBL] [Abstract][Full Text] [Related]
89. Clinical significance of K-ras and BRAF mutations in Chinese colorectal cancer patients.
Shen H; Yuan Y; Hu HG; Zhong X; Ye XX; Li MD; Fang WJ; Zheng S
World J Gastroenterol; 2011 Feb; 17(6):809-16. PubMed ID: 21390154
[TBL] [Abstract][Full Text] [Related]
90. Vitamin C intake and colorectal cancer survival according to KRAS and BRAF mutation: a prospective study in two US cohorts.
Shi S; Wang K; Ugai T; Giannakis M; Cazaubiel J; Chan AT; Giovannucci EL; Nowak JA; Meyerhardt JA; Ogino S; Song M
Br J Cancer; 2023 Nov; 129(11):1793-1800. PubMed ID: 37775523
[TBL] [Abstract][Full Text] [Related]
91. High
Liu H; Zhang L; Wang Y; Wu R; Shen C; Li G; Shi S; Mao Y; Hua D
Medicina (Kaunas); 2023 Jun; 59(6):. PubMed ID: 37374338
[No Abstract] [Full Text] [Related]
92. Fibroblast Growth Factor Receptor 1 (FGFR1) Amplification Detected by Droplet Digital Polymerase Chain Reaction (ddPCR) Is a Prognostic Factor in Colorectal Cancers.
Bae JM; Wen X; Kim TS; Kwak Y; Cho NY; Lee HS; Kang GH
Cancer Res Treat; 2020 Jan; 52(1):74-84. PubMed ID: 31096734
[TBL] [Abstract][Full Text] [Related]
93. Activation of ERK1/2 occurs independently of KRAS or BRAF status in endometrial cancer and is associated with favorable prognosis.
Mizumoto Y; Kyo S; Mori N; Sakaguchi J; Ohno S; Maida Y; Hashimoto M; Takakura M; Inoue M
Cancer Sci; 2007 May; 98(5):652-8. PubMed ID: 17388789
[TBL] [Abstract][Full Text] [Related]
94. The relationships of OSBPL3 expression with KI-67 expression and KRAS mutations in CRC: implications for diagnosis and prognosis.
Zhang M; Meng L; Zhang Z; Wu J; Chen X; Wang Y; He J
BMC Med Genomics; 2022 Dec; 15(1):259. PubMed ID: 36517805
[TBL] [Abstract][Full Text] [Related]
95. The implication of BRAF mutation in advanced colorectal cancer.
O'Riordan E; Bennett MW; Daly L; Power DG
Ir J Med Sci; 2022 Dec; 191(6):2467-2474. PubMed ID: 34877621
[TBL] [Abstract][Full Text] [Related]
96. SOX2 expression is regulated by BRAF and contributes to poor patient prognosis in colorectal cancer.
Lundberg IV; Löfgren Burström A; Edin S; Eklöf V; Öberg Å; Stenling R; Palmqvist R; Wikberg ML
PLoS One; 2014; 9(7):e101957. PubMed ID: 25010701
[TBL] [Abstract][Full Text] [Related]
97. Systematic review of tumour budding and association with common mutations in patients with colorectal cancer.
Hatthakarnkul P; Quinn JA; Matly AAM; Ammar A; van Wyk HC; McMillan DC; Edwards J
Crit Rev Oncol Hematol; 2021 Nov; 167():103490. PubMed ID: 34619332
[TBL] [Abstract][Full Text] [Related]
98. EARLY-ONSET COLORECTAL CANCER: AN ELEVEN-YEAR ANALYSIS OF CLINICOPATHOLOGICAL CHARACTERISTICS AT A TERTIARY HEALTHCARE CENTER.
Piñerúa-Gonsálvez JF; Zambrano-Infantino RDC; Rizzo-Rodríguez MA; Dueñas-Diez A; Fernández-Salazar L
Arq Gastroenterol; 2023; 60(3):315-321. PubMed ID: 37792760
[TBL] [Abstract][Full Text] [Related]
99. Clinical and molecular profile of young adults with early-onset colorectal cancer: Experience from four Australian tertiary centers.
Siu DHW; Ali A; Tjokrowidjaja A; De Silva M; Lee J; Clingan PR; Aghmesheh M; Brungs D; Mapagu C; Goldstein D; O'Neill S; Liauw WS; Sjoquist KM; Thomas D; Pavlakis N; Clarke SJ; Diakos C; Chantrill LA
Asia Pac J Clin Oncol; 2022 Dec; 18(6):660-668. PubMed ID: 35098672
[TBL] [Abstract][Full Text] [Related]
100. CRISPR screens identify a novel combination treatment targeting BCL-X
Jung HR; Oh Y; Na D; Min S; Kang J; Jang D; Shin S; Kim J; Lee SE; Jeong EM; An JY; Sung CO; Lee WS; Lee C; Cho SY
Oncogene; 2021 May; 40(18):3287-3302. PubMed ID: 33846570
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
